उपज चिंताएं बढ़ने से एशियाई स्टॉक फिसलता है
- द्वाराInvesting.com
- •
Sinovac Biotech Ltd., a biopharmaceutical company, focuses on the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. Its product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella; pneumococcal polysaccharide vaccine; quadrivalent influenza vaccine; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was formerly known as Net-Force System Inc. and changed its name to Sinovac Biotech Ltd. in October 2003. The company was incorporated in 1999 and is based in Beijing, China.